MLA Diagnostics

A multi-parameter non-invasive melanoma risk assessment tool

Problem

Melanoma is the most deadly form of skin cancer. It is fast-growing, yet with early detection it can be treated successfully with surgical excision. The biggest concern with melanoma is the high risk of recurrence and progression. Most melanoma mortality occurs in patients with a recurrence of the disease that was early-stage (Stage I or Stage II) at the time of diagnosis. As many as 20-30% of early-stage melanoma patients will develop a recurrence that with current clinical indicators was cleared as low risk. A concerningly high risk for patients with emotional, financial and psychological consequences. Prognostic tools that can identify high risk patients are of paramount importance to allow for more personalized surveillance and treatment strategies.

Solution

MLA Diagnostics has developed an integrated multi-parameter risk assessment tool used to identify melanoma patients who based on molecular and clinical risk factors have a high chance of their melanoma spreading or recurring. The molecular assay is easily implemented into current laboratory workflows and enriches clinical and pathological information to support clinicians in clinical decision making and managing their patients treatment.